Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Barr/AstraZeneca tamoxifen antitrust suit dismissed

Executive Summary

AstraZeneca and Barr "authorized generic" agreement for breast cancer agent Nolvadex did not violate antitrust laws, Brooklyn, N.Y. federal judge rules. Complaints from consumers and third-party payors argued that 1993 agreement under which Barr marketed generic tamoxifen until August 2002 kept other generics off market. Judge's ruling dismisses all state and federal claims. A prior Justice Department investigation into settlement was closed without action (1"The Pink Sheet" Sept. 3, 2001, p. 20)...

You may also be interested in...

Barr/AstraZeneca Tamoxifen Settlement Under Investigation By State AGs

An inquiry by several states into Barr's tamoxifen agreement with AstraZeneca is the latest indication that states are not deferring to the Federal Trade Commission in investigating patent settlements.

Health Sector On High Alert As Wuhan Coronavirus Spreads

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts